Comparison 3.

THIORIDAZINE vs PLACEBO

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early	1	236	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.28, 0.69]
2 Adverse effects: various outcomes	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 drowsiness	1	165	Risk Ratio (M-H, Fixed, 95% CI)	5.46 [2.62, 11.36]
2.2 restlessness	1	165	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.69, 1.48]
2.3 constipation	1	165	Risk Ratio (M-H, Fixed, 95% CI)	1.72 [0.83, 3.57]
2.4 nausea or upper gastrointestinal distress	1	165	Risk Ratio (M-H, Fixed, 95% CI)	8.13 [2.58, 25.59]
2.5 dryness of mouth or throat	1	165	Risk Ratio (M-H, Fixed, 95% CI)	5.69 [2.09, 15.50]
2.6 dizziness, faintness, weakness	1	165	Risk Ratio (M-H, Fixed, 95% CI)	4.47 [1.61, 12.41]
2.7 muscle rigidity	1	165	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.16, 1.85]
2.8 nasal congestion	1	165	Risk Ratio (M-H, Fixed, 95% CI)	3.25 [1.14, 9.31]
2.9 facial rigidity	1	165	Risk Ratio (M-H, Fixed, 95% CI)	1.63 [0.51, 5.19]
2.10 tremor of hands, arms, face	1	165	Risk Ratio (M-H, Fixed, 95% CI)	2.44 [0.82, 7.25]
2.11 headache	1	165	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.32, 2.06]
2.12 loss of associated movements	1	165	Risk Ratio (M-H, Fixed, 95% CI)	0.16 [0.01, 3.34]
2.13 akathesis-restlessness of feet	1	165	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [0.33, 5.49]